2 active not recruiting, 2 completed, 1 terminated. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Recurrent Lung Adenocarcinoma: new trials by email Literature Review of Recurrent Lung Adenocarcinoma trials Research Report on Recurrent Lung Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer Pembrolizumab, Pemetrexed, Carboplatin - Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 101 | 2020-11-16 | 2026-10-08 |
| Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Rucaparib - Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation | Phase 2 | Completed | SWOG Cancer Research Network | 64 | 2019-04-16 | 2025-05-21 |
| Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer Nivolumab, Stereotactic Body Radiation Therapy - Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 140 | 2017-06-26 | 2026-06-22 |
| A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib Trametinib, Erlotinib - Lung Adenocarcinoma, Lung Cancer | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 24 | 2017-03-01 | 2024-04-02 |
| S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Bevacizumab, Carboplatin, Cetuximab - Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma | Phase 3 | Terminated | SWOG Cancer Research Network | 1333 | 2009-07-15 | 2023-05-23 |
Adenocarcinoma of Lung (5) · Lung Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Carcinoma, Neuroendocrine (1)
Adenocarcinoma (5) · Carcinoma (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Respiratory Tract Neoplasms (5) · Thoracic Neoplasms (5) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Neoplasms (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1)
Carboplatin (2) · Bevacizumab (1) · Cetuximab (1) · Disulfides (1) · Erlotinib Hydrochloride (1) · Geriatric Assessment (1) · Immunoglobulin G (1) · Nivolumab (1) · Paclitaxel (1) · Pemetrexed (1) · Radiosurgery (1) · Taxes (1) · pembrolizumab (1) · rucaparib (1) · trametinib (1)
SWOG Cancer Research Network (2) · Alliance for Clinical Trials in Oncology (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1)
United States (5) · Mexico (1)
Aminah Jatoi, MD (1) · Helena Yu, MD (1) · Joe Y Chang (1) · Jonathan W Riess (1) · Roy Herbst (1)
PMID 29169877, PMID 34753703, PMID 37478883, PMID 42161344
U10CA180888 (2), U10CA032102 (1), UG1CA189823 (1)